In a German patient survey, respondents described using fewer prescription medicines after starting medical cannabis. Self-reported changes do not prove that cannabis caused the reduction. Among more than 3,500 respondents, many reported a reduced need for painkillers, sleeping medicines or other treatments.
Bloomwell’s April 2026 report described an average reduction of 84.5% across medication categories. Many respondents also reported fewer medication-related adverse effects and better everyday wellbeing.
These findings are notable, particularly for people with long-term conditions whose existing treatment may offer insufficient relief. It is essential, however, to understand what the figures mean and which conclusions they support.
3,528 medical cannabis patients surveyed
German medical cannabis platform Bloomwell published ‘The Cannabis Barometer’, covering the first quarter of 2026 and exploring patients’ experiences with other prescription medicines and adverse effects.
The survey involved 3,528 people using medical cannabis. They were asked which prescription medicines they had used beforehand and how their use had changed.
Nonopioid painkillers were the most common prior medicines, used by 55.8% of respondents. Sleeping medicines had been used by 51.5%, antidepressants by 26.8% and opioid painkillers by 18.8%.
Many participants therefore had treatment needs related to pain, sleep and other long-term health problems.
What does the 84.5% figure mean?
The report’s most widely highlighted figure was 84.5%.
Bloomwell presented this as the average patient-reported reduction across medication categories. The average complete-discontinuation figure across categories was 58.9%. These are category-based aggregates, rather than independently verified prescription-register changes in quantities for all 3,528 patients.
They do not mean that every participant reduced medication by exactly 84.5%, or that 84.5% stopped all medicines.
The aggregates reflect different medication groups and patients’ own accounts.
Particularly notable figures concerned sleeping medicines, opioid painkillers and methylphenidate-containing medicines.
Sleeping medicines: many reported lower use
Among previous users of sleeping medicines, 93.6% reported reducing use by at least half. Complete discontinuation was reported by 75.5% of that medication group.
This suggests that some patients experienced changes in their sleep treatment after starting medical cannabis.
Sleep quality affects wellbeing, work, mood, concentration and everyday functioning. This is why cannabinoid sleep research attracts interest.
Self-reported changes do not establish medical cannabis as a proven substitute for conventional insomnia treatment. Controlled clinical findings have been inconsistent.
Our article ‘CBD and Sleep: What Does the Science Say?’ examines CBD and recent research in more detail.
Opioid painkillers: a possible research direction
For opioid painkiller users, the report described an average reduction of 83.9%, with 61% reporting complete discontinuation.
Opioids are potent medicines with an important role in certain pain conditions. Long-term use can nevertheless involve tolerance, dependence and other serious adverse effects.
Medical cannabis is therefore being investigated as a possible additional option for chronic pain.

If high-quality trials confirmed that cannabinoids reduced opioid requirements in particular patient groups without worsening outcomes, this could meaningfully expand treatment options.
Bloomwell’s survey provides a starting point for investigation, but does not prove cannabis alone caused the reported changes.
ADHD medicines: reported reductions in methylphenidate
The report separately examined methylphenidate medicines, used for conditions including attention deficit hyperactivity disorder, or ADHD.
Users reported an average reduction of 88.4%, with complete discontinuation reported by 77.3% of that medication group.
These findings require particularly careful interpretation.
ADHD is a complex neurodevelopmental condition. Current knowledge does not establish cannabis as a replacement for methylphenidate. Cannabinoid effects on attention, impulsivity and other symptoms need more substantial clinical research.
The survey’s value lies mainly in identifying research questions, rather than providing grounds to change treatment guidelines.
Patients also described fewer adverse effects
Bloomwell also asked about medication-related adverse effects.
According to the report, 60.7% no longer experienced previous medication-related adverse effects, while 37.9% reported a reduction.
Unchanged effects were reported by 1.1%, and worsening by 0.3%.
Many respondents therefore perceived a positive change in their treatment experience after starting medical cannabis.
This does not make medical cannabis free of adverse effects. THC-containing preparations can cause dizziness, drowsiness, attention problems and other unwanted effects.
Assessment must consider possible symptom relief alongside adverse effects and medicine interactions.
Could medical cannabis improve quality of life?
The report also explored everyday functioning.
Better concentration was reported by 67.8%, more social contact by 61.9% and less absence from work by 53.9%.
Such measures matter because chronic disease treatment is not judged solely through symptoms: sleep, work, movement and social interaction also count.
A patient’s own quality-of-life assessment is valuable medical information.
Other influences, however, include concurrent treatment, changing health and expectations.
Independent studies capable of more objective comparison are therefore needed to assess these positive accounts.
What does the survey establish scientifically?
A patient survey must be distinguished from a randomised clinical trial. This survey was organised by a medical cannabis service provider itself. That context matters, while patients’ positive experiences remain worth studying.
Respondents described their own experiences after starting cannabis. Comparable groups were not randomly assigned to different treatments.
The published data also do not establish independent verification of every medication change against medical records or prescriptions.
It is therefore uncertain how much of the reduction was caused specifically by cannabis treatment.
The organiser’s background also matters: Bloomwell operates in Germany’s medical cannabis industry and has a commercial interest in its development.
This does not make thousands of patients’ accounts worthless. They can help researchers identify important questions and design stronger clinical studies.
They should not, however, be presented as proof that medical cannabis reduces prescription requirements for all patients.
Why does Germany’s experience matter?
Germany is accumulating substantial practical experience with medical cannabis.
Prescribing has been possible for years, with regulatory changes taking effect in 2024.
This creates opportunities to gather further information on outcomes, potential benefits and problems.
A possible strength is expanding physicians’ treatment options, particularly when previous care has provided inadequate relief or troublesome adverse effects.
The same treatment will not suit everyone. Benefits depend on the condition, preparation, patient’s health and other medicines.
Our article ‘Cannabis: What It Is, How It Works and What You Should Know’ explains the plant’s active compounds and uses.
What could Estonia learn?
Medical cannabis in Estonia operates under its medicines framework, which differs from Germany’s.
Germany offers an opportunity to observe how broader options affect healthcare practice.
If independent studies confirm reduced need for other medicines and better quality of life in particular groups, this could also matter for Estonian healthcare.
Reliable data, long-term safety studies and clear treatment guidelines are needed.
Our article ‘Cannabis Legality in Estonia: Laws, Rules and Reality in 2026’ discusses medical use and Estonia’s restrictions.
Summary
Bloomwell’s survey of 3,528 patients identified substantial reported changes in medicine use and wellbeing.
Sleeping medicines and opioids were particularly interesting, with many users in those categories reporting reductions.
The 84.5% figure is an average across medication categories, rather than a clinically established treatment effect for every patient.
The findings nevertheless justify further research into possible benefits.
If high-quality trials establish reduced requirements for other medicines in specific circumstances, cannabinoids could broaden options and help reduce the burden of medication-related adverse effects.
Patients’ experiences are a valuable starting point for determining where medical cannabis may help.
This article is informational and does not replace medical advice. Do not change or stop prescription medicines solely on the basis of a patient survey.
Original source: Bloomwell Group, ‘The Cannabis Barometer’, Q1 2026 (PDF). The report covers 3,528 respondents and category-specific figures for sleeping medicines, opioids and methylphenidate. Its findings support further independent clinical research.
Archive photo: Niki Nagy / original, Pexels License. Cropped to 16:9 and optimised as WebP.
